NuProbe to commercialize Wyss Institute's new technology to facilitate precision medicine

NuProbe Global will commercialize the Wyss Institute's DNA nanotechnology-based variant-detecting method as a fast, low-cost and multiplexed molecular diagnostic for different disease areas, including cancer and infectious diseases.